|
MYL12A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 9.62729995723777E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.64779997927178E-09 |
| Normal-vs-Stage2 |
7.968200E-01 |
| Normal-vs-Stage3 |
3.63559999883023E-08 |
| Normal-vs-Stage4 |
3.88789999999917E-05 |
| Stage1-vs-Stage2 |
6.67030000012225E-07 |
| Stage1-vs-Stage3 |
6.105200E-01 |
| Stage1-vs-Stage4 |
7.973800E-01 |
| Stage2-vs-Stage3 |
1.8183000000116E-06 |
| Stage2-vs-Stage4 |
1.009380E-04 |
| Stage3-vs-Stage4 |
9.109800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.21829995986178E-09 |
| Normal-vs-AfricanAmerican |
3.602300E-03 |
| Normal-vs-Asian |
1.73390000024476E-07 |
| Caucasian-vs-AfricanAmerican |
9.639200E-01 |
| Caucasian-vs-Asian |
2.670600E-01 |
| AfricanAmerican-vs-Asian |
4.462000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.66700000031805E-07 |
| Normal-vs-Female |
3.06299999808246E-08 |
| Male-vs-Female |
5.726200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.43979997000588E-10 |
| Normal-vs-Age(41-60Yrs) |
4.34719999997668E-07 |
| Normal-vs-Age(61-80Yrs) |
1.436240E-02 |
| Normal-vs-Age(81-100Yrs) |
5.8504999999931E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.040100E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.022700E-03 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.653800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.213900E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.373820E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.936400E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.775530E-03 |
| Classical-VS-Follicular |
1.27379995440435E-10 |
| Classical-VS-Other |
6.019600E-01 |
| Classical-VS-Normal |
1.91110460789901E-11 |
| Tall-VS-Follicular |
1.30749999716073E-09 |
| Tall-VS-Other |
6.507900E-02 |
| Tall-VS-Normal |
3.83249998403556E-09 |
| Follicular-VS-Other |
1.607830E-01 |
| Follicular-VS-Normal |
8.993400E-01 |
| Other-VS-Normal |
3.027000E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.561900E-03 |
| Normal-vs-N1 |
4.76319999997976E-07 |
| N0-vs-N1 |
6.567400E-04 |
|
|
